According to a recent LinkedIn post from Cooler Heads, the company is highlighting a patient interview about its Amma scalp cooling system. The post centers on an individual’s experience using Amma during cancer treatment and her reasons for choosing scalp cooling as part of her care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same post describes Amma as an FDA-cleared scalp cooling device intended to help reduce hair loss in adult cancer patients receiving treatment for solid tumors. For investors, the emphasis on real-world patient stories and regulatory clearance underscores Cooler Heads’ focus on adoption in oncology settings, which could support long-term demand, strengthen clinical credibility, and enhance the company’s competitive positioning in the supportive cancer care market.